Recent Class Action Lawsuit Filed Against Vistagen Therapeutics, Impacts on Investors

Investors Urged to Act: Class Action Lawsuit Against Vistagen Therapeutics

The landscape of investment can change rapidly, and for those involved with Vistagen Therapeutics, Inc. (NASDAQ: VTGN), recent events warrant immediate attention. Pomerantz LLP, a distinguished law firm specializing in securities law, has initiated a class action lawsuit against Vistagen. This legal action raises concerns about possible securities fraud or other illicit practices by the company and its leadership.

The class action revolves around claims that Vistagen and certain officers neglected their fiduciary responsibilities, potentially misleading investors regarding the company's financial health and product efficacy. It's essential for anyone who has invested in Vistagen during the specified class period to understand the implications of this lawsuit and consider their options moving forward.

Key Details About the Lawsuit

On December 17, 2025, Vistagen issued a press release that sent shockwaves through the investment community: their PALISADE-3 Phase 3 trial of the drug Fasedienol for treating social anxiety disorder did not meet its primary endpoint. Notably, the study was intended to demonstrate significant improvement over placebo, yet it failed to show such results, leading to disappointing regulatory and market responses.

As a direct consequence of this announcement, Vistagen’s stock plummeted by over 80%, a notable decline that reflected investor panic and loss of confidence. For shareholders, this news was particularly dire, with the stock closing at just $0.861 per share, a stark contrast to its previous value.

Upcoming Deadlines

Investors impacted by this downturn are reminded that there are critical deadlines approaching. To be actively involved in the lawsuit, individuals must apply to be designated as Lead Plaintiff by March 16, 2026. This position allows individuals to advocate for the interests of all class members. Interested parties are encouraged to reach out to Pomerantz LLP for assistance with joining the class action, which can be done via email or phone.

Those who reach out should provide their contact information, number of shares purchased, and any additional details that may assist the firm in their investigation. The necessary documentation, including a copy of the complaint, is readily available at Pomerantz's official website, helping investors remain informed.

The Legacy of Pomerantz LLP

Founded by Abraham L. Pomerantz, often revered as the pioneer in class action litigation, Pomerantz LLP has established a reputation for securing substantial recoveries for victims of securities fraud and corporate misconduct. With over 85 years of experience, the firm continues to fight ardently for the rights of investors, leveraging their extensive expertise to navigate complex legal waters in such cases.

As they move forward, Vistagen investors are encouraged to stay informed and act promptly to protect their interests in the wake of this lawsuit.

For more detailed insights regarding the lawsuit or to proceed with joining the class action, investors can contact the firm directly, ensuring they understand the potential ramifications on their investments. This situation illustrates the critical importance of vigilance among investors, especially in sectors characterized by volatility and rapid change.